BL
PCRX icon

Balentine LLC’s Pacira BioSciences PCRX Stock Holding History

Balentine LLC’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-454
Closed -$19K – 460
2015
Q3 		$19K Buy
454
+120
+36% +$7.35K ﹤0.01% 288
2015
Q2 		$24K Hold
334
– – ﹤0.01% 247
2015
Q1 		$27K Buy
+334
New +$33.9K 0.01% 211

Other funds holding PCRX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
MCM
Marsico Capital Management Denver, Colorado $3.4B AUM 51.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
HCM
Hoplite Capital Management New York $15.1M AUM 27.41% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balentine LLC's PCRX Position: Q4 2015 in Review

Balentine LLC sold out of Pacira BioSciences (PCRX) in Q4 2015, closing a stake of 454 shares — an estimated $19K sold.

Balentine LLC first reported a position in PCRX in Q1 2015 and held it in 3 quarters. The position peaked at $27K in Q1 2015. 214 funds tracked by Wall St. Rank hold PCRX as of Q4 2015.

  • Balentine LLC reported no remaining Pacira BioSciences position as of Q4 2015 after selling out during the quarter.
  • Balentine LLC sold 454 Pacira BioSciences shares in Q4 2015, an estimated $19K.
  • Balentine LLC first reported a position in Pacira BioSciences in Q1 2015 and held it in 3 quarters.
  • Balentine LLC's Pacira BioSciences position peaked at $27K in Q1 2015.
  • 214 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2015.

Based on Balentine LLC's 13F filing for Q4 2015, filed 16 Feb 2016.